Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
Operating Expenses
Immunoprecise Antibodies Ltd
Operating Expenses Peer Comparison
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Operating Expenses
-CA$18.5m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Operating Expenses
-$275.2m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-96%
|
CAGR 10-Years
N/A
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Operating Expenses
-CA$10m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-45%
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Operating Expenses
-CA$1.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
Innovotech Inc
XTSX:IOT
|
Operating Expenses
-CA$1.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
2%
|
See Also
What is Immunoprecise Antibodies Ltd's Operating Expenses?
Operating Expenses
-18.5m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Operating Expenses amounts to -18.5m CAD.
What is Immunoprecise Antibodies Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 3Y
-37%
Over the last year, the Operating Expenses growth was -52%. The average annual Operating Expenses growth rates for Immunoprecise Antibodies Ltd have been -37% over the past three years .